Progress in immune‐based therapies for type 1 diabetes

Summary Immune‐based therapies that prevent type 1 diabetes or preserve metabolic function remaining at diagnosis have become a major objective for funding agencies and international trial consortia, and receive backing from notable patient advocate groups. The development of immune‐based therapeuti...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental immunology Vol. 172; no. 2; pp. 186 - 202
Main Authors: Herrath, M., Peakman, M., Roep, B.
Format: Journal Article
Language:English
Published: England Oxford University Press 01.05.2013
Blackwell Science Inc
Subjects:
Autoimmune diseases
Autoimmunity
Diabetes
Diabetes Mellitus, Type 1 - immunology
Diabetes Mellitus, Type 1 - therapy
Humans
immunotherapy
Immunotherapy - methods
Medical research
Mortality
Review
Self Tolerance
ISSN:0009-9104, 1365-2249, 1365-2249
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Immune‐based therapies that prevent type 1 diabetes or preserve metabolic function remaining at diagnosis have become a major objective for funding agencies and international trial consortia, and receive backing from notable patient advocate groups. The development of immune‐based therapeutic strategies in this arena requires a careful balancing of the risks of the therapy against the potential benefits, because many individuals are diagnosed or identified as being at increased risk of disease in early childhood, a period when manipulation of the developing immune system should be undertaken with caution. In addition, a therapy exists (daily insulin injection) that is life‐saving in the acute stages of disease and can be used effectively over a lifetime as maintenance. Conversely, the disease is increasing in incidence; is peaking in ever‐younger age groups; carries significant risk of increased morbidity and early mortality; and remains difficult to manage effectively in many settings. With these issues in mind, in this article we review progress towards immune‐based strategies for this chronic autoimmune disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
All authors contributed equally to this article.
ISSN:0009-9104
1365-2249
1365-2249
DOI:10.1111/cei.12085